European Union - English - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

New Zealand - English - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - albumin 50 g/l;   - solution for infusion - 5 % - active: albumin 50 g/l   excipient: n-acetyl-dl-tryptophan octanoic acid potassium sodium water for injection - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - albumin 200 g/l - solution for infusion - 20 % - active: albumin 200 g/l excipient: n-acetyl-dl-tryptophan octanoic acid potassium sodium water for injection - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - pramipexole 2hcl monohydrate eqv pramipexole - tablet - 0.125mg - pramipexole 2hcl monohydrate eqv pramipexole 0.125mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - pramipexole 2hcl monohydrate eqv pramipexole - tablet - 1mg - pramipexole 2hcl monohydrate eqv pramipexole 1mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - pramipexole dihydrochloride monohydrate - tablet, extended release - 0.375mg - pramipexole dihydrochloride monohydrate 0.375mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - pramipexole dihydrochloride monohydrate - tablet, extended release - 1.500mg - pramipexole dihydrochloride monohydrate 1.500mg

United Kingdom - English - myHealthbox

sandoz gmbh - pregabalin - hard capsule - 200 mg - anti-epileptics, other anti-epileptics - it is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of generalised anxiety disorder (gad) in adults

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: povidone; ascorbyl palmitate; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.